Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy
Monitoring of circulating angiogenic factors in dendritic cell-based cancer immunotherapy
复制标题
DOI：
10.1002/cncr.11776
复制
发表时间：
2003-11-15
期刊：
影响因子：
6.2
通讯作者：
Stift, A
中科院分区：
文献类型：
--
作者：
Brostjan, C;Bayer, A;Stift, A
背景最近已经进入临床试验的恶性疾病患者的一种有希望的治疗方法是基于用负载有肿瘤抗原的自体树突状细胞进行疫苗接种。然而，用于监测临床和免疫应答的适当测定仍在争论中。近年来，血管生成标志物的测定在恶性疾病患者的诊断和预后方面显示出相当大的潜力，因为肿瘤的生长和扩散是由血管生成、新血管的形成所促进的。作者建立了一种测量三种血管生成调节剂的血浆水平的方法：血管内皮生长因子、血小板衍生的内皮细胞生长因子和血小板反应蛋白-1。健康对照组的血管生成血液特征被表征并与一组恶性疾病患者进行比较。最后，在树突状细胞为基础的癌症免疫治疗过程中监测循环血管生成因子的水平。血管生成介质的基线水平在健康个体中差异很大，但每个个体的值一致。在晚期疾病患者中，循环血管生成因子的血液水平显著升高，并且对基于树突状细胞的免疫治疗高度敏感。据我们所知，目前的报告是第一个分析在树突状细胞为基础的免疫治疗血管生成因子的循环水平。作者观察到治疗后血管生成血液特征发生了显著变化，该变化与免疫应答的诱导相关。(C)2003年，美国癌症协会。
BACKGROUND. A promising treatment approach for patients with malignant disease that recently has found its way into clinical trials is based on vaccination with autologous dendritic cells loaded with tumor antigens. However, adequate assays for monitoring clinical and immunologic responses still are under debate. In recent years, the determination of angiogenic markers has shown considerable potential in the diagnosis and prognosis of patients with malignant disease, because tumor growth and spread are promoted by angiogenesis, the formation of new blood vessels.METHODS. The authors established a method for measuring the plasma levels of three modulators of angiogenesis: vascular endothelial growth factor, plateletderived endothelial cell growth factor, and thrombospondin-1. The angiogenic blood profile of a healthy control group was characterized and compared with a group of patients with malignant disease. Ultimately, levels of circulating angiogenic factors were monitored in the course of dendritic cell-based cancer immunotherapy.RESULTS. Baseline levels of angiogenic mediators varied substantially among healthy individuals but showed consistent values for each individual. Blood levels of circulating angiogenic factors were elevated significantly in patients with advanced disease and were highly sensitive to dendritic cell-based immunotherapy.CONCLUSIONS. To our knowledge, the current report was the first to analyze circulating levels of angiogenic factors during dendritic cell-based immunotherapy. The authors observed a noteworthy change in the angiogenic blood profile with treatment, and this change was correlated with the induction of an immunologic response. (C) 2003 American Cancer Socieol.